Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban Treatment
  • Giuseppe Di Tano
    Division of Cardiology, Ospedale di Cremona, Italy
  • Luigi Moschini
    Division of Cardiology, Ospedale di Cremona, Italy
  • Marco Loffi
    Division of Cardiology, Ospedale di Cremona, Italy
  • Gianluca Galeazzi
    Division of Cardiology, Ospedale di Cremona, Italy
  • Sophie Testa
    Haemostasis and Thrombosis Center, Ospedale di Cremona, Italy
  • Gian Battista Danzi
    Division of Cardiology, Ospedale di Cremona, Italy


Viral diseases, pneumonia, thrombosis, pulmonary embolism, rivaroxaban


Introduction: SARS-CoV-2 infection may predispose patients to thrombotic disease. Patients with COVID-19 pneumonia who are receiving non-vitamin K antagonists or direct oral anticoagulants for chronic disease are usually switched to heparin treatment during hospitalization. However, information about the most appropriate antithrombotic therapy after the acute infection phase is lacking.
Case Description: We report the case of a patient with chronic atrial fibrillation who was recently hospitalized for severe COVID-19 pneumonia. Four weeks after discharge he experienced an episode of an acute pulmonary embolism while on rivaroxaban therapy with adequate drug plasma levels, and in the absence of strong predisposing risk factors.
Conclusion: This case highlights the risk of thrombotic complications after COVID-19 infection, raises some concern about their underlying mechanisms, and supports the use of effective anti-thrombotic therapy.



  • Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020;75(23):2950–2973.

  • Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19.J Thromb Haemost 2020;18(5):1023–1026.

  • Testa S, Paoletti O, Giorgi-Pierfranceschi M, Pan A. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients. Intern Emerg Med 2020 April 15;1–3. doi: 10.1007/s11739-020-02331-1 [Epub ahead of print].

  • Cohen AT, Gitt AK, Bauersachs R, Fronk EM, Laeis P, Mismetti P, et al. The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry. Thromb Haemost 2017;117(7):1326–1337.

  • Beyer-Westendorf J, Förster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC Registry. Blood 2014;124:955–962.

  • Fox SE, Akmatbekov A, Harbert JL, Li G, Brown JQ, Vander Heide RS. Pulmonary and cardiac pathology in COVID-19: the first autopsy series from New Orleans. medRxiv Preprint 2020. doi:

  • Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020;395(10234):1417–1418.

  • Thachil J. The versatile heparin in COVID-19. J Thromb Haemost 2020;18:1020–1022.
  • Views: 1503
    HTML downloads: 1125
    PDF downloads: 618

    Published: 2020-06-18
    Issue: 2020: Vol 7 No 7 (view)

    How to cite:
    Di Tano G, Moschini L, Loffi M, Galeazzi G, Testa S, Danzi GB. Late Pulmonary Embolism after COVID-19 Pneumonia despite Adequate Rivaroxaban Treatment. EJCRIM 2020;7 doi:10.12890/2020_001790.

    Most read articles by the same author(s)